

29 Jan 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Merck & Co. tells *Scrip* oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 27 January 2023, including: [Merck & Co., Inc.](#) tells *Scrip* oncology will remain a key priority; [Johnson & Johnson](#) is responsibly cautious on growth; [Takeda Pharmaceutical Co. Ltd.](#) pays big for [HUTCHMED \(China\) Limited](#) drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position](#)" - *Scrip*, 19 Jan, 2023.)

(Also see "[J&J Lays Out 'Responsibly Cautious' Growth Outlook](#)" - *Scrip*, 24 Jan, 2023.)

(Also see "[Takeda Pays Big For De-Risked HutchMed CRC Drug](#)" - *Scrip*, 23 Jan, 2023.)

(Also see "[Industry Looks At IRA Drawbacks And Silver Linings](#)" - *Scrip*, 20 Jan, 2023.)

(Also see "[No Fast Track For Lecanemab In EU Disappoints Eisai](#)" - *Scrip*, 19 Jan, 2023.)

[Click here to explore this interactive content online](#) 